MedTrace Logo

Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study

NCT02902744 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2017-08-22

No results posted yet for this study

Summary

Primary Objective:

• To collect post-approval safety data related to intraocular pressure (IOP) after one or more injections of Iluvien as standard of care in subjects with diabetic macular edema (DME).

Secondary Objectives:

• To collect visual and anatomic outcome data after one or more injections of Iluvien as standard of care in subjects with diabetic macular edema (DME).

Conditions

Interventions

DRUG

ILUVIEN®

Patients will receive Iluvien as the standard of care treatment for diabetic macular edema.

Sponsors & Collaborators

Principal Investigators

  • Gulnar Hafiz, MD, MPH · Wilmer Eye Institute, Johns Hopkins Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2017-08-18
Completion
2017-08-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02902744 on ClinicalTrials.gov